We identified in the TCGA-PRAD cohort the intermediate-risk tumors (n = 119; see Methods and Additional file 1: Methods) and the high-risk tumors (n = 174; see Methods and Additional file 1: Methods), and found that the expression of PVT1 in the high-risk group was significantly (t-test p = 0.01) higher than in the intermediate-risk group (Fig. 4c). Here, PVT1 is linked to prostate adenocarcinoma.